Aandelen in “Fabricage van farmaceutische preparaten”

Aandeel Datum Koers Evolutie
vlag Qualigen Therapeutics Inc 30/10 3,050 USD
+6,64% 		+6,64%

Nieuws over “Fabricage van farmaceutische preparaten”

30/10 · Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London · Persbericht

30/10 · Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London · Persbericht

30/10 · Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development · Persbericht

30/10 · Galapagos kondigt wijzigingen aan in de Raad van Bestuur om de strategische focus op business development te versnellen · Persbericht

30/10 · Eli Lilly verrast met sterk derde kwartaak en verhoogt de vooruitzichten fors · Bolero.be

30/10 · Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update · Persbericht

30/10 · Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance · Persbericht

29/10 · Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) · Persbericht

29/10 · The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year · Persbericht

29/10 · Savara Inc. (SVRA) Shareholders Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

29/10 · Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025 · Persbericht

29/10 · Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results · Persbericht

29/10 · Perrigo Announces Quarterly Dividend · Persbericht

29/10 · Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States · Persbericht

29/10 · FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria · Persbericht

29/10 · AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo · Persbericht

29/10 · Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting · Persbericht

29/10 · Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update · Persbericht

29/10 · LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound · Persbericht

29/10 · Immunic to Participate in Industry and Investor Conferences in November · Persbericht

29/10 · Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System · Persbericht

Mijn selecties